دورية أكاديمية
أعرض في EDS

Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer.
المؤلفون: Santos NJ; Department of Structural and Functional BIology, Institute of Bioscience of Botucatu (IBB), São Paulo State University, Botucatu 18618-689, SP, Brazil.; Department of Structural and Functional Biology, Institute of Biology (IB), UNICAMP-State University of Campinas, Campinas 13083-970, SP, Brazil., Barquilha CN; Department of Structural and Functional BIology, Institute of Bioscience of Botucatu (IBB), São Paulo State University, Botucatu 18618-689, SP, Brazil.; Department of Structural and Functional Biology, Institute of Biology (IB), UNICAMP-State University of Campinas, Campinas 13083-970, SP, Brazil., Barbosa IC; Department of Structural and Functional BIology, Institute of Bioscience of Botucatu (IBB), São Paulo State University, Botucatu 18618-689, SP, Brazil.; Department of Structural and Functional Biology, Institute of Biology (IB), UNICAMP-State University of Campinas, Campinas 13083-970, SP, Brazil., Macedo RT; Botucatu School of Medicine (FMB), São Paulo State University, Botucatu 01049-010, SP, Brazil., Lima FO; Botucatu School of Medicine (FMB), São Paulo State University, Botucatu 01049-010, SP, Brazil., Justulin LA; Department of Structural and Functional BIology, Institute of Bioscience of Botucatu (IBB), São Paulo State University, Botucatu 18618-689, SP, Brazil., Barbosa GO; Department of Structural and Functional Biology, Institute of Biology (IB), UNICAMP-State University of Campinas, Campinas 13083-970, SP, Brazil., Carvalho HF; Department of Structural and Functional Biology, Institute of Biology (IB), UNICAMP-State University of Campinas, Campinas 13083-970, SP, Brazil., Felisbino SL; Department of Structural and Functional BIology, Institute of Bioscience of Botucatu (IBB), São Paulo State University, Botucatu 18618-689, SP, Brazil.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2021 Aug 12; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Gene Expression Profiling/*methods , Prostatic Neoplasms/*pathology , Syndecan-1/*genetics , Syndecan-3/*genetics , Syndecan-4/*genetics, Aged ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Transplantation ; Prognosis ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Protein Array Analysis ; Sequence Analysis, RNA ; Survival Analysis ; Syndecan-1/metabolism ; Syndecan-3/metabolism ; Syndecan-4/metabolism ; Syntenins/genetics ; Syntenins/metabolism
مستخلص: Prostate cancer (PCa) is the leading cause of cancer-associated mortality in men, and new biomarkers are still needed. The expression pattern and protein tissue localization of proteoglycans of the syndecan family (SDC 1-4) and syntenin-1 (SDCBP) were determined in normal and prostatic tumor tissue from two genetically engineered mouse models and human prostate tumors. Studies were validated using SDC 1-4 and SDCBP mRNA levels and patient survival data from The Cancer Genome Atlas and CamCAP databases. RNAseq showed increased expression of Sdc1 in Pb-Cre4/Pten f/f mouse Pca and upregulation of Sdc3 expression and downregulation of Sdc2 and Sdc4 when compared to the normal prostatic tissue in Pb-Cre4/Trp53 f/f -;Rb1 f/f mouse tumors. These changes were confirmed by immunohistochemistry. In human PCa, SDC 1-4 and SDCBP immunostaining showed variable localization. Furthermore, Kaplan-Meier analysis showed that patients expressing SDC3 had shorter prostate-specific survival than those without SDC3 expression (log-rank test, p = 0.0047). Analysis of the MSKCC-derived expression showed that SDC1 and SDC3 overexpression is predictive of decreased biochemical recurrence-free survival ( p = 0.0099 and p = 0.045, respectively), and SDC4 overexpression is predictive of increased biochemical recurrence-free survival ( p = 0.035). SDC4 overexpression was associated with a better prognosis, while SDC1 and SDC3 were associated with more aggressive tumors and a worse prognosis.
References: Eur Urol. 2012 Oct;62(4):577-87. (PMID: 22695242)
Dis Markers. 2015;2015:796052. (PMID: 26420915)
Methods Mol Med. 2005;103:89-101. (PMID: 15542899)
Biochim Biophys Acta. 2015 Apr;1855(2):276-300. (PMID: 25829250)
Nat Cell Biol. 2012 Jun 03;14(7):677-85. (PMID: 22660413)
Am J Pathol. 2018 Apr;188(4):1094-1103. (PMID: 29355516)
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. (PMID: 31061129)
Nat Rev Urol. 2012 Feb 21;9(4):196-206. (PMID: 22349653)
Cell Tissue Res. 2015 Sep;361(3):833-44. (PMID: 25715761)
Biomed Res Int. 2013;2013:214864. (PMID: 23844358)
Adv Cancer Res. 2019;144:137-191. (PMID: 31349898)
EBioMedicine. 2017 Mar;17:5-6. (PMID: 28286059)
EMBO Mol Med. 2018 Mar;10(3):. (PMID: 29437778)
ISRN Oncol. 2013 Apr 18;2013:680136. (PMID: 23691363)
Nat Rev Urol. 2018 Apr;15(4):222-234. (PMID: 29460925)
Mol Cancer Ther. 2019 Nov;18(11):1997-2007. (PMID: 31345950)
Cancer Res. 2018 Jun 1;78(11):2852-2863. (PMID: 29572229)
Cancer Cell. 2010 Jul 13;18(1):11-22. (PMID: 20579941)
Cancer Metastasis Rev. 2020 Sep;39(3):769-781. (PMID: 32410111)
Mol Carcinog. 2010 Apr;49(4):363-73. (PMID: 20082322)
Am J Cancer Res. 2019 Jul 01;9(7):1309-1328. (PMID: 31392072)
BMC Gastroenterol. 2015 Oct 30;15:152. (PMID: 26518017)
Prostate. 2003 Apr 1;55(1):20-9. (PMID: 12640657)
APMIS. 2004 Feb;112(2):89-97. (PMID: 15056224)
Asian J Androl. 2011 May;13(3):476-80. (PMID: 21317913)
Cancer Manag Res. 2019 Jun 06;11:5271-5291. (PMID: 31239778)
Histol Histopathol. 2014 Feb;29(2):177-89. (PMID: 24150912)
Mol Biol Cell. 1994 Jul;5(7):797-805. (PMID: 7812048)
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3271-5. (PMID: 1565618)
FEBS J. 2017 Jan;284(1):27-41. (PMID: 27790852)
J Biol Chem. 2012 Nov 23;287(48):40339-49. (PMID: 23060448)
Mol Carcinog. 2016 Sep;55(9):1378-86. (PMID: 26259043)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Cancers (Basel). 2019 Dec 23;12(1):. (PMID: 31878027)
Cancer Treat Res Commun. 2021;27:100312. (PMID: 33485180)
Int J Mol Sci. 2021 Apr 19;22(8):. (PMID: 33921767)
Cell Res. 2015 Apr;25(4):412-28. (PMID: 25732677)
Int J Mol Sci. 2018 Aug 22;19(9):. (PMID: 30135409)
Biotechnol Appl Biochem. 2021 Jan 12;:. (PMID: 33432665)
J Membr Biol. 2015 Dec;248(6):991-1004. (PMID: 26065901)
PLoS One. 2013 Sep 16;8(9):e74250. (PMID: 24066126)
Prostate. 2017 May;77(13):1312-1324. (PMID: 28744948)
Biol Cell. 2015 Oct;107(10):331-41. (PMID: 26032692)
Am J Pathol. 2011 Jul;179(1):502-12. (PMID: 21703427)
Cancer Res. 2006 Aug 15;66(16):7889-98. (PMID: 16912162)
Cancer Cell. 2003 Sep;4(3):209-21. (PMID: 14522255)
Urology. 2004 Feb;63(2):402-7. (PMID: 14972511)
EBioMedicine. 2015 Jul 29;2(9):1133-44. (PMID: 26501111)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Biomed Res Int. 2015;2015:453801. (PMID: 26558271)
Int J Cancer. 2021 Mar 1;148(5):1245-1259. (PMID: 33152121)
BJU Int. 2010 Aug;106(3):418-23. (PMID: 20002675)
Nat Rev Cancer. 2008 Apr;8(4):268-78. (PMID: 18337732)
World J Gastroenterol. 2014 Mar 21;20(11):3018-24. (PMID: 24659893)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
Methods Mol Biol. 2011;724:23-35. (PMID: 21370004)
Nat Rev Mol Cell Biol. 2003 Dec;4(12):926-37. (PMID: 14685171)
Int J Exp Pathol. 2015 Feb;96(1):1-10. (PMID: 25546317)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):78-82. (PMID: 19786981)
Aging (Albany NY). 2021 Jul 6;13(13):17442-17461. (PMID: 34229299)
Urol Oncol. 2018 Jun;36(6):312.e9-312.e15. (PMID: 29628317)
Matrix Biol. 2015 Mar;42:11-55. (PMID: 25701227)
Front Pharmacol. 2016 Feb 02;7:10. (PMID: 26869927)
J Pathol. 2013 Dec;231(4):495-504. (PMID: 24549646)
Oxid Med Cell Longev. 2020 Jan 20;2020:2148562. (PMID: 32411320)
Tumour Biol. 2015 Mar;36(3):1731-8. (PMID: 25361632)
FEBS J. 2019 Aug;286(15):2994-3007. (PMID: 30932318)
Cell Tissue Res. 2010 Jan;339(1):31-46. (PMID: 19597846)
World J Gastroenterol. 2017 Jun 7;23(21):3907-3914. (PMID: 28638231)
معلومات مُعتمدة: 2015/26175-7, 2016/09532-3, 2019/19644-1 Fundação de Amparo à Pesquisa do Estado de São Paulo
فهرسة مساهمة: Keywords: gene expression; outcome; prognostic marker; prostate cancer; survival; syndecan
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (SDC1 protein, human)
0 (SDC3 protein, human)
0 (SDC4 protein, human)
0 (SDCBP protein, human)
0 (Syndecan-1)
0 (Syndecan-3)
0 (Syndecan-4)
0 (Syntenins)
تواريخ الأحداث: Date Created: 20210827 Date Completed: 20210915 Latest Revision: 20210915
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8395474
DOI: 10.3390/ijms22168669
PMID: 34445387
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms22168669